APTO – Aptose Biosciences Inc
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Total Analysts: 7
Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.